AN OPEN-LABEL, SINGLE-TREATMENT, SINGLE-PERIOD, SINGLE DOSE, CLINICAL PHASE 1 STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LIVE MEASLES AND RUBELLA VACCINE, (MULTIPLE DOSE VIAL FORMULATION) OF M/s CADILA HEALTHCARE LTD., INDIA IN HEALTHY, ADULT, MALE, HUMAN SUBJECTS UNDER FASTING CONDITION
Latest Information Update: 29 Aug 2016
At a glance
- Drugs Measles and rubella virus vaccine (Primary)
- Indications Measles; Rubella
- Focus Adverse reactions
- Sponsors Cadila Healthcare
- 31 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 11 Sep 2012 New trial record